The obesity drug landscape
CagriSema did not arrive in a vacuum. It competes in the most active area of drug development in a generation, against…
Where CagriSema sits in a crowded field
CagriSema did not arrive in a vacuum. It competes in the most active area of drug development in a generation, against approved heavyweights (semaglutide, tirzepatide) and other investigational multi-hormone drugs (retatrutide, survodutide, eloralintide).
This unit places CagriSema honestly on that map: competitive on weight loss, distinctive in mechanism, but behind on the cardiovascular, liver, and durability evidence its rivals have accumulated.
Key terms
Weight loss, side by side
The first question everyone asks is "how much weight?" Placed against its rivals, CagriSema is competitive but not dominant: it sits in the same roughly 22-24% band as tirzepatide and retatrutide, well above semaglutide alone, but it does not clearly lead.
A crucial caveat sits under this chart: these numbers come from different trials, timepoints, and populations, so the bars are suggestive, not a fair head-to-head. No trial has directly compared CagriSema to tirzepatide or retatrutide. The honest read is that CagriSema is firmly in the top tier of weight-loss efficacy, but claims that it is "the strongest" outrun the evidence.
These bars are from separate trials, not a head-to-head. CagriSema is competitive with tirzepatide and retatrutide, not proven superior to them.